News Image

MediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Treatment of Chlorine-Induced Acute Respiratory Distress Syndrome

Provided By GlobeNewswire

Last update: May 14, 2024

LA JOLLA, Calif., May 14, 2024 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office for a pending patent application which covers MN-166 (ibudilast) for the treatment of chlorine-induced acute respiratory distress syndrome (ARDS).

Read more at globenewswire.com

MEDICINOVA INC

NASDAQ:MNOV (7/24/2025, 12:27:43 PM)

1.255

-0.01 (-0.4%)



Find more stocks in the Stock Screener

Follow ChartMill for more